Anemia is a common complication for patients who are undergoing chemotherapy, and one that has implications for patients’ quality of life, especially with respect to fatigue. During the European Society for Medical Oncology 2018 Congress, held October 19-23, 2018, in Munich, Germany, Jérôme Desrame, MD, reported on results of the CIROCO study, which assessed fatigue in patients with chemotherapy-induced anemia who were treated with biosimilar epoetin alfa.
Anemia is a common complication for patients who are undergoing chemotherapy, and one that has implications for patients’ quality of life, especially with respect to fatigue. During the European Society for Medical Oncology 2018 Congress, held October 19-23, 2018, in Munich, Germany, Jérôme Desrame, MD, reported on results of the CIROCO study, which assessed fatigue in patients with chemotherapy-induced anemia who were treated with biosimilar epoetin alfa.
The CIROCO study, funded by Sandoz, is a noninterventional, prospective, multicenter study of 538 adult patients who had 2 or more planned cycles of chemotherapy. The patients all had chemotherapy-induced anemia, and were receiving Sandoz’s biosimilar epoetin alfa (approved in the European Union under the brand names Epoetin Alfa Hexal, Abseamed, and Binocrit). Data were collected at inclusion, after a 2- to 3-month follow-up period, and after 4 to 6 cycles of chemotherapy.
Patients and their physicians separately assessed fatigue using a visual analogue scale (VAS) on a scale of 0 to 10; additionally, patients assessed their quality of life using the European Organization for the Research and Treatment of Cancer core quality of life questionnaire (EORTC QLQ C30).
Desrame and colleagues reported data for the subgroup of 434 patients with solid tumors. At baseline, mean hemoglobin was 9.7 (±0.8) g/dL. The mean increase in hemoglobin was 1.2 (±1.4) g/dL at 2 to 3 months of followup, and 0.4 (±1.5) g/dL after 4 to 6 cycles of chemotherapy.
In the safety population of 464 patients, 32.5% had adverse events (AEs) and 13.8% had serious AEs. However, only 3% of patients had AEs that were considered related to the study treatment.
In the full-analysis set population, between the 2- to 3-month follow-up measurement and the 4- to 6-cycle of chemotherapy measurement, the mean change in fatigue VAS score as reported by the patients was 5.2% (±92.6). The mean change in EORTC QLQ C30 score was 29.9 % (±98.0). Using the fatigue VAS, the physician assessment of fatigue was consistent with patient perceptions at all measurement timepoints.
The researchers concluded that biosimilar epoetin alfa was effective in treating these patients’ anemia, with improvements demonstrated in both hemoglobin levels and quality of life measurements.
Reference
Desrame J, et al. Correlation between fatigue evaluated with a visual analog scale (VAS) and quality of life (QoL) in cancer patients treated with biosimilar epoetin alfa for chemotherapy-induced anemia (CIA): the CIROCO study. Presented at the European Society for Medical Oncology (ESMO) 2018 Congress, October 19-23, 2018; Munich, Germany. Abstract 1790P. https://cslide.ctimeetingtech.com/esmo2018/attendee/confcal/show/session/258.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
FDA's Expanded Access: From Laetrile to Right to Try, Ethical Debates Over Early Drug Access
April 28th 2025Christopher T. Robertson, JD, PhD, reviewed the history and ethical landscape of providing access to drugs before FDA approval, highlighting the crucial role of clinical trials and ethical safeguards at the 2025 Festival of Biologics USA.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Unlocking Biosimilar Potential in Specialty Pharmacies With Legislative Support, Formulary Changes
April 24th 2025Sophia Humphreys, PharmD, MHA, BCBBS, emphasized that legislative support and formulary changes are crucial for overcoming unique challenges in specialty pharmacies and driving the growth of biosimilar adoption, which has significant cost saving potential in the next decade.
Decade of Biosimilars Yields $36 Billion in Savings and Strengthens Supply Chain
April 24th 2025Dracey Poore, MS, director of biosimilars and emerging therapies at Cardinal Health, highlighted that biosimilars saved $36 billion over the last decade by improving patient access and the supply chain, but continued education and a robust pipeline are crucial for future growth.